Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 17.66m |
Free float | 11.73m |
P/E (TTM) | 11.96 |
Market cap | 844.88m EUR |
EPS (TTM) | 4.00 EUR |
--
More ▼
Announcements
- EQS-News: Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
- EQS-News: Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
- Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
- EQS-News: Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
- EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
- EQS-News: Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
More ▼